Home / Stocks / Corona Remedies Limited
CORONA

Corona Remedies Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹2,236.7

Change

-19.5 (-0.86%)

Open

₹2,273.0

Prev. Close

₹2,256.2

Day High

₹2,278.2

Day Low

₹2,220.0

Volume Analysis

Traded

25,615

Delivered

13,881

Delivery %

54.19%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (29.5%)
  • •Strong operating margin (21.0%)

Weaknesses (0)

No signal for this stock

Opportunities (3)

  • •Strong 3-year EPS growth (29.7%)
  • •Strong 3-year revenue growth (16.7%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹2,328.14 ₹2,303.17 ₹2,269.94 ₹2,244.97 ₹2,211.74 ₹2,186.77 ₹2,153.54
Fibonacci ₹2,303.17 ₹2,280.94 ₹2,267.2 ₹2,244.97 ₹2,222.74 ₹2,209.0 ₹2,186.77
Camarilla ₹2,252.71 ₹2,247.37 ₹2,242.04 ₹2,244.97 ₹2,231.37 ₹2,226.03 ₹2,220.7

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+59.49%

1 Week

-4.5%

1 Month

+10.68%

3 Months

+4.39%

6 Months

+32.77%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

25.55%

Net margin 13.28% × asset turnover 1.21x × equity multiplier 1.59x

Company Overview

Sector

Healthcare

Market Cap

₹14,010 Cr

P/E (TTM)

63.6

ROE

29.5%

Book Value

₹132.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Corona Remedies Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 74/100. The strongest factor is Financial Strength (100/100), while Valuation (2/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (29.5%); strong operating margin (21.0%). Strong 3-year EPS growth (29.7%).

TopFund Score — Fundamentals Quality

74/100 — Good

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

91

Valuation

2

Cash Flow

72

Corporate Governance

90

Momentum

69

Institutional Ownership

65

Business Quality

90

Risk & Volatility

89

Liquidity

50

From Screener.in

  • +Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%
  • +Company has been maintaining a healthy dividend payout of 29.3%
  • −Stock is trading at 17.4 times its book value

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Transcript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the second quarter and half year ended September 30, 2026

NPPA issued demand notice of ₹4.88 crore on November 3, 2026 for alleged DPCO 2013 violation.

Audio recording of Q2/H1 FY27 earnings conference call is available on company website.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 314 298 294 347 361 342 353 422 441
Expenses + 247 228 239 277 283 259 291 329 345
Operating Profit 67 69 54 70 78 83 62 93 96
OPM % 21.0% 23.0% 18.0% 20.0% 22.0% 24.0% 18.0% 22.0% 22.0%
Other Income + 2 1 2 2 2 -17 4 3 3
Interest 3 2 2 2 2 2 1 3 3
Depreciation 9 10 10 9 9 9 10 13 15
Profit before tax 57 58 44 61 70 55 55 80 81
Tax % 25.0% 23.0% 28.0% 24.0% 25.0% 25.0% 17.0% 25.0% 25.0%
Net Profit + 43 45 32 46 52 41 45 60 60
EPS in Rs 7 7 5 8 9 7 7 10 10
Raw PDF — — — — — — — — —
YoY Sales growth — — — — 15 15 20 22 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 509 601 576 617 884 1,014 1,196 1,403 1,559
Expenses + 444 509 471 600 756 859 956 1,109 1,225
Operating Profit 66 93 105 18 128 156 241 294 334
OPM % 13.0% 15.0% 18.0% 2.9% 14.0% 15.0% 20.0% 21.0% 21.0%
Other Income + 3 3 5 7 7 5 6 -9 -7
Interest 1 2 2 5 4 14 11 7 8
Depreciation 14 16 16 20 20 28 37 38 48
Profit before tax 54 77 92 -1 111 118 199 240 271
Tax % 35.0% 24.0% 24.0% -49.0% 23.0% 24.0% 25.0% 23.0% —
Net Profit + 35 59 70 0 85 90 149 185 207
EPS in Rs 7 12 14 0 14 15 24 30 34
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 20.0% 25.0% 30.0% 33.0% —
Sales growth — 18 -4 7 — 15 18 17 20

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 204 263 333 270 347 419 545 686 744
Borrowings + 13 47 50 34 28 159 86 165 115
Other Liabilities + 71 94 144 157 159 191 237 293 326
Total Liabilities 293 408 532 511 595 831 930 1,205 1,247
Fixed Assets + 80 81 164 162 185 384 370 554 698
CWIP 4 42 0 14 65 121 186 143 22
Investments 9 7 37 14 32 26 26 26 0
Other Assets + 200 278 330 321 314 301 348 482 526
Total Assets 293 408 532 511 595 831 930 1,205 1,247
Equity Capital 5 5 5 51 61 61 61 61 61

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 19 43 79 98 103 157 190 229
Cash from Investing Activity + -23 -50 -102 -66 -50 -267 -84 -256
Cash from Financing Activity + 4 30 0 -30 -45 99 -107 25
Net Cash Flow -1 23 -23 2 8 -11 0 -1
Free Cash Flow 19 1 6 64 9 -129 99 56
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 49 65 101 557 100 112 97 95

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 69.0% → 69.0%
  Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 22.41% 21.75% 14.47% 10.35%
Promoters 69.0% 69.0% 69.0% 69.0%
FII 1.84% 2.25% 3.63% 4.21%
DII 6.77% 7.02% 12.9% 16.44%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Corona Remedies Limited (this stock) 14,010 63.6 17.34 29.5%
Sudeep Pharma Limited 13,545 71.9 14.14 25.2%
Vijaya Diagnostic Cen Ltd 14,524 71.3 13.69 18.9%
Marksans Pharma Limited 13,347 23.8 4.0 15.2%
Jubilant Pharmova Ltd 14,883 50.4 2.08 6.53%
Rainbow Childrens Med Ltd 12,607 43.0 7.34 16.7%
Indegene Limited 15,640 36.7 4.67 14.4%

Which Mutual Funds Hold Corona Remedies Limited?

Frequently Asked Questions about Corona Remedies Limited

Community Sentiment

What are other investors saying about Corona Remedies Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.